Zevra Q4 2019 Earnings Report
Key Takeaways
KemPharm reported Q4 2019 revenue of $1.4 million from research and development services, and a net loss of $6.0 million, or $0.18 per share. The company's cash and investments totaled $3.6 million as of December 31, 2019. They anticipate KP415 NDA submission in Q1 2020.
KP415 NDA remains on track for Q1 2020 submission.
Q4 2019 revenue was $1.4 million from research and development services.
Q4 2019 net loss was $6.0 million, or $0.18 per share.
Cash and investments totaled $3.6 million as of December 31, 2019.
Zevra
Zevra
Forward Guidance
KemPharm expects research and development services revenue to continue through FY 2020 and beyond as they provide consultation services to support their partner in their commercial preparation activities for KP415 and with the potential initiation of the product development plan for KP484.